*Refresh the page if the below document does not appear.
By 2027, around 25% of Dr. Reddy's goods will be first to market: Co-chairman
As part of its attempts to increase affordability, Dr. Reddy’s Laboratories wants to guarantee that at least 25% of its product releases are first-to-market by 2027, according to its Co-Chairman and Managing Director.
Investors taken aback with Gland Pharma's acquisition in Europe
Gland Pharma plans to strengthen product mix at Cenexi, but the high cost base of industrial facilities in wealthy countries makes increasing profitability challenging. The firm is buying the Cenexi group, a European company with notably lower profit margins than Gland Pharma.
NPPA released its 2nd list of draft ceiling pricing for 43 formulations
The National Pharmaceutical Pricing Authority (NPPA) has announced the second batch of proposed ceiling prices for 43 formulations. As per the draft calculation sheet, the prices of two formulations have been cut by more than half, and the prices of three others have been decreased by 40-50 percent.
Roivant and Pfizer form a joint venture to develop an anti-inflammatory medication
Roivant Sciences and Pfizer established a unit to create RVT-3101, a medication that both companies hope to use to treat inflammatory bowel disease. A mid-stage trial is now evaluating the drug’s efficacy as a treatment for ulcerative colitis.
USFDA approves Ferring Pharma's REBYOTA, first fecal microbiota product
REBYOTA, an unique first-in-class microbiotabased live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in patients 18 years of age and older, has been approved by the US Food and Drug Administration (USFDA).
Africa's healthcare sector offers prospects for India
India wants to strengthen its connections with Africa. The healthcare sector has been suggested as one area where trade across the continents can develop. Young African doctors are thus encouraged to complete their education in India, and in the meantime, Indian healthcare companies are spreading throughout Africa.
GSK seeks to expand PD-1 Jemperli in endometrial cancer in light of new trial success
New critical data could help GSK expand into a broader endometrial cancer population as it strives to match its PD-1 blocking antibody Jemperli to Merck’s superstar Keytruda. GSK intends to file regulatory submissions based on the trial results in the first half of 2023.
